Robert Stuart to Humans
This is a "connection" page, showing publications Robert Stuart has written about Humans.
Connection Strength
0.683
-
Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia. Leuk Lymphoma. 2020 03; 61(3):631-640.
Score: 0.026
-
Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. Leuk Res. 2019 10; 85:106197.
Score: 0.025
-
Ankle Lateral Ligament Augmentation Versus the Modified Brostr?m-Gould Procedure: A 5-Year Randomized Controlled Trial. Am J Sports Med. 2019 03; 47(3):659-666.
Score: 0.024
-
Phase 3 results for vosaroxin/cytarabine in the subset of patients =60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica. 2018 11; 103(11):e514-e518.
Score: 0.023
-
Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Leuk Lymphoma. 2015 Mar; 56(3):645-9.
Score: 0.019
-
REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. Br J Haematol. 2015 Mar; 168(6):796-805.
Score: 0.018
-
Primary ankle ligament augmentation versus modified Brostrom-Gould procedure: a 2-year randomized controlled trial. ANZ J Surg. 2015 Jan; 85(1-2):44-8.
Score: 0.018
-
Developmental therapeutics in acute myelogenous leukemia: are there any new effective cytotoxic chemotherapeutic agents out there? Curr Hematol Malig Rep. 2013 Jun; 8(2):156-62.
Score: 0.017
-
Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange. Eur J Haematol. 2012 Nov; 89(5):432-4.
Score: 0.016
-
Vosaroxin : a novel antineoplastic quinolone. Expert Opin Investig Drugs. 2012 Aug; 21(8):1223-33.
Score: 0.015
-
Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure. Bone Marrow Transplant. 2012 Nov; 47(11):1403-8.
Score: 0.015
-
Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. Transfusion. 2012 Nov; 52(11):2375-81.
Score: 0.015
-
Overcoming HLA-DPB1 donor specific antibody-mediated haematopoietic graft failure. Br J Haematol. 2010 Oct; 151(1):94-6.
Score: 0.014
-
Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. Bone Marrow Transplant. 2011 Apr; 46(4):523-8.
Score: 0.014
-
Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant. 2011 Jan; 46(1):64-9.
Score: 0.013
-
Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside. Expert Opin Investig Drugs. 2010 Mar; 19(3):427-36.
Score: 0.013
-
Salivary gland neoplasms. Curr Treat Options Oncol. 2004 Feb; 5(1):11-26.
Score: 0.009
-
Autologous bone marrow transplant in a patient with sickle cell disease and diffuse large B-cell lymphoma. Transplant Proc. 2003 Dec; 35(8):3089-92.
Score: 0.009
-
Oral cancer treatment. Curr Treat Options Oncol. 2003 02; 4(1):27-41.
Score: 0.008
-
Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome. Blood Adv. 2021 09 28; 5(18):3528-3539.
Score: 0.007
-
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). Blood Adv. 2021 07 13; 5(13):2775-2787.
Score: 0.007
-
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021 Jul; 8(7):e481-e491.
Score: 0.007
-
Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia. JCO Oncol Pract. 2021 04; 17(4):e497-e505.
Score: 0.007
-
Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. Hematol Oncol. 2020 Aug; 38(3):353-362.
Score: 0.007
-
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med. 2019 10 31; 381(18):1728-1740.
Score: 0.006
-
Locally advanced breast cancer in Saudi Arabia: high frequency of stage III in a young population. Med Oncol. 1999 Jul; 16(2):95-103.
Score: 0.006
-
Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 09; 25(9):1744-1755.
Score: 0.006
-
A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias. Cancer Chemother Pharmacol. 2019 07; 84(1):163-173.
Score: 0.006
-
Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma. Eur J Cancer. 2019 05; 113:87-95.
Score: 0.006
-
Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. Blood Adv. 2019 02 26; 3(4):508-518.
Score: 0.006
-
Malignant ovarian germ cell tumours -- a survival and prognostic analysis. Acta Oncol. 1999; 38(4):455-60.
Score: 0.006
-
Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. Blood Adv. 2018 11 13; 2(21):2922-2936.
Score: 0.006
-
Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. Biol Blood Marrow Transplant. 2019 01; 25(1):73-85.
Score: 0.006
-
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol. 2018 09 10; 36(26):2684-2692.
Score: 0.006
-
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. N Engl J Med. 2018 Jun 21; 378(25):2386-2398.
Score: 0.006
-
A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia. Biol Blood Marrow Transplant. 2018 08; 24(8):1581-1589.
Score: 0.006
-
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017 08; 18(8):1061-1075.
Score: 0.005
-
Reassessment of Rebleeding Risk of Forrest IB (Oozing) Peptic Ulcer Bleeding in a Large International Randomized Trial. Am J Gastroenterol. 2017 03; 112(3):441-446.
Score: 0.005
-
Electronic clinical trial protocol distribution via the World-Wide Web: a prototype for reducing costs and errors, improving accrual, and saving trees. J Am Med Inform Assoc. 1997 Jan-Feb; 4(1):25-35.
Score: 0.005
-
Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery. J Hematol Oncol. 2016 08 17; 9(1):71.
Score: 0.005
-
The influence of serum tumor necrosis factor-alpha and interleukin-6 concentrations on nonhematologic toxicity and hematologic recovery in patients with acute myelogenous leukemia. Exp Hematol. 1995 Nov; 23(12):1256-60.
Score: 0.005
-
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015 Sep; 16(9):1025-1036.
Score: 0.005
-
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. J Clin Oncol. 2015 Apr 10; 33(11):1252-7.
Score: 0.005
-
Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. Leuk Lymphoma. 2015; 56(9):2569-78.
Score: 0.005
-
Elevation of c-MYC disrupts HLA class II-mediated immune recognition of human B cell tumors. J Immunol. 2015 Feb 15; 194(4):1434-45.
Score: 0.005
-
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015 Feb 26; 125(9):1367-76.
Score: 0.005
-
A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia. Haematologica. 2015 Feb; 100(2):231-7.
Score: 0.005
-
Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res. 2014 Nov 15; 20(22):5652-62.
Score: 0.005
-
Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma. Blood. 2014 Sep 18; 124(12):1915-25.
Score: 0.005
-
Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol. 2014 Oct 10; 32(29):3264-74.
Score: 0.005
-
Similar dynamics of intraapheresis autologous CD34+ recruitment and collection efficiency in patients undergoing mobilization with or without plerixafor. Transfusion. 2014 Dec; 54(12):3131-7.
Score: 0.004
-
Medical therapy of prostate cancer. J S C Med Assoc. 1994 May; 90(5):231-6.
Score: 0.004
-
Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: implications for risk-stratification. Biol Blood Marrow Transplant. 2014 Feb; 20(2):222-8.
Score: 0.004
-
Autologous bone marrow transplantation for leukemia. Semin Oncol. 1993 Oct; 20(5 Suppl 6):40-54.
Score: 0.004
-
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013 Jun 13; 121(24):4854-60.
Score: 0.004
-
G-CSF improves granulocytopenia in Felty's syndrome without flare-up of arthritis. Am J Hematol. 1993 Feb; 42(2):230-1.
Score: 0.004
-
Association of age with fluorescence in situ hybridization abnormalities in multiple myeloma reveals higher rate of IGH translocations among older patients. Leuk Lymphoma. 2012 Dec; 53(12):2444-8.
Score: 0.004
-
Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. J Clin Oncol. 2012 Jul 10; 30(20):2492-9.
Score: 0.004
-
Reducing arrhythmias associated with central venous catheter insertion or exchange. Nutrition. 1992 Jan-Feb; 8(1):19-21.
Score: 0.004
-
Pharmacokinetics of leucovorin metabolites in human plasma as a function of dose administered orally and intravenously. J Natl Cancer Inst. 1991 Dec 18; 83(24):1806-12.
Score: 0.004
-
Case report: isoimmune inhibition of erythropoiesis following ABO-incompatible bone marrow transplantation. Am J Med Sci. 1991 Dec; 302(6):369-73.
Score: 0.004
-
Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agents. Am J Hematol. 2011 Aug; 86(8):699-701.
Score: 0.004
-
Role of glutathione in the in vitro synergism between 4-hydroperoxy-cyclophosphamide and cisplatin in leukemia cell lines. Cancer Res. 1991 May 15; 51(10):2536-41.
Score: 0.004
-
Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. Blood. 2011 Jun 02; 117(22):5941-52.
Score: 0.004
-
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. Clin Cancer Res. 2011 May 15; 17(10):3388-97.
Score: 0.004
-
Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function. Transfusion. 2011 Sep; 51(9):1995-2000.
Score: 0.004
-
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood. 2011 Mar 24; 117(12):3294-301.
Score: 0.004
-
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias. Clin Cancer Res. 2011 Mar 01; 17(5):1140-6.
Score: 0.004
-
Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2011 Aug; 17(8):1176-81.
Score: 0.003
-
Safety and tolerability of high-dose intravenous esomeprazole for prevention of peptic ulcer rebleeding. Adv Ther. 2011 Feb; 28(2):150-9.
Score: 0.003
-
Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. Br J Haematol. 2010 Dec; 151(5):430-4.
Score: 0.003
-
Iatrogenic immunodeficiency-associated lymphoproliferative disease of the Hodgkin lymphoma-like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitis. Am J Hematol. 2010 Aug; 85(8):627-9.
Score: 0.003
-
Helical tomotherapy for extramedullary hematopoiesis involving the pericardium in a patient with chronic myeloid leukemia. Jpn J Radiol. 2010 Jul; 28(6):476-8.
Score: 0.003
-
Perioperative nutrition in cancer patients. Nutrition. 1990 Jul-Aug; 6(4 Suppl):4S-6S.
Score: 0.003
-
Translocation t(3;8;9)(p25;p21;q34) in a patient with features of 8p11 myeloproliferative syndrome: a unique case and review of the literature. Leuk Res. 2010 Nov; 34(11):1543-4.
Score: 0.003
-
Incidence of arrhythmia with central venous catheter insertion and exchange. JPEN J Parenter Enteral Nutr. 1990 Mar-Apr; 14(2):152-5.
Score: 0.003
-
Synergism between 4-hydroperoxycyclophosphamide and cisplatin: importance of incubation sequence and measurement of cisplatin accumulation. Biochem Pharmacol. 1990 Feb 01; 39(3):607-9.
Score: 0.003
-
Cost effectiveness of high-dose intravenous esomeprazole for peptic ulcer bleeding. Pharmacoeconomics. 2010; 28(3):217-30.
Score: 0.003
-
Cellular glutathione as a protective agent against 4-hydroperoxycyclophosphamide cytotoxicity in K-562 cells. Cancer Chemother Pharmacol. 1990; 26(6):397-402.
Score: 0.003
-
Combinations of 4-hydroperoxycyclophosphamide (4-HC) and cisplatin for bone marrow purging in autologous marrow transplantation: an update. Prog Clin Biol Res. 1990; 333:57-68.
Score: 0.003
-
Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia. J Clin Oncol. 2010 Feb 10; 28(5):815-21.
Score: 0.003
-
Extensive involvement of the gastrointestinal tract by a de novo presentation of the monoblastic type of myeloid sarcoma: a case report of a rare entity that is often misdiagnosed. Am J Med Sci. 2009 Dec; 338(6):513-6.
Score: 0.003
-
Hematopoietic stem cell origin of human fibroblasts: cell culture studies of female recipients of gender-mismatched stem cell transplantation and patients with chronic myelogenous leukemia. Exp Hematol. 2009 Dec; 37(12):1464-71.
Score: 0.003
-
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. Blood. 2009 Nov 05; 114(19):4027-33.
Score: 0.003
-
Overexpression of nucleolin in engrafted acute myelogenous leukemia cells. Am J Hematol. 2009 Aug; 84(8):535-8.
Score: 0.003
-
Toxicity and survival outcomes of hyperfractionated split-course reirradiation and daily concurrent chemotherapy in locoregionally recurrent, previously irradiated head and neck cancers. Head Neck. 2009 Apr; 31(4):493-502.
Score: 0.003
-
Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial. Ann Intern Med. 2009 Apr 07; 150(7):455-64.
Score: 0.003
-
Accumulation of tetrahydrofolates in human plasma after leucovorin administration. Cancer Chemother Pharmacol. 1989; 23(6):353-7.
Score: 0.003
-
In vitro synergism of 4-hydroperoxycyclophosphamide and cisplatin: relevance for bone marrow purging. Cancer Chemother Pharmacol. 1989; 23(3):129-34.
Score: 0.003
-
Proximal esophageal stenosis in head and neck cancer patients after total laryngectomy and radiation. ORL J Otorhinolaryngol Relat Spec. 2008; 70(4):229-35.
Score: 0.003
-
Tetraploidy and 5q deletion in myelodysplastic syndrome: a case report. Cancer Genet Cytogenet. 2008 May; 183(1):64-8.
Score: 0.003
-
Defects in HLA class II antigen presentation in B-cell lymphomas. Leuk Lymphoma. 2008 Feb; 49(2):353-5.
Score: 0.003
-
Long-term survival following salvage reirradiation with concurrent chemotherapy for recurrent head and neck cancer. J S C Med Assoc. 2008 Feb; 104(2):36-9.
Score: 0.003
-
Intravenous esomeprazole for prevention of peptic ulcer re-bleeding: rationale/design of Peptic Ulcer Bleed study. Aliment Pharmacol Ther. 2008 Apr; 27(8):666-77.
Score: 0.003
-
Posttransplantation lymphoproliferative disorder--the great mimic in liver transplantation: appraisal of the clinicopathologic spectrum and the role of Epstein-Barr virus. Liver Transpl. 2007 Jun; 13(6):904-12.
Score: 0.003
-
Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA. Blood. 2007 Apr 01; 109(7):3069-75.
Score: 0.003
-
Jumping translocation of 1q in BCR/ABL-positive acute lymphoblastic leukemia. Cancer Genet Cytogenet. 2007 Jan 01; 172(1):90-1.
Score: 0.003
-
Hematologic and cytogenetic remission of 5q-refractory anemia after syngeneic bone marrow transplantation. Am J Med. 1986 Mar; 80(3):503-7.
Score: 0.003
-
Human multilineage progenitor cell sensitivity to 4-hydroperoxycyclophosphamide. Exp Hematol. 1985 May; 13(4):295-8.
Score: 0.002
-
Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. Eur J Cancer. 2004 Oct; 40(15):2260-8.
Score: 0.002
-
High complete pathological response in locally advanced breast cancer using paclitaxel and cisplatin. Breast Cancer Res Treat. 2000 Aug; 62(3):237-44.
Score: 0.002
-
Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor. Bone Marrow Transplant. 2000 Jul; 26(1):1-16.
Score: 0.002
-
Carbenicillin-trimethoprim/sulfamethoxazole versus carbenicillin-gentamicin as empiric therapy of infection in granulocytopenic patients. A prospective, randomized, double-blind study. Am J Med. 1980 Jun; 68(6):876-85.
Score: 0.002
-
Adding high-dose tamoxifen to CHOP does not influence response or survival in aggressive non-Hodgkin's lymphoma: an interim analysis of a randomized phase III trial. Med Oncol. 2000 Feb; 17(1):39-46.
Score: 0.002
-
Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol. 2000 Jan; 18(1):148-57.
Score: 0.002
-
The utilization of midazolam as a pharmacologic adjunct to endotracheal intubation by paramedics. Prehosp Emerg Care. 2000 Jan-Mar; 4(1):14-8.
Score: 0.002
-
Primary gastric non-Hodgkin's lymphoma: clinical features, management, and prognosis of 185 patients with diffuse large B-cell lymphoma. Ann Oncol. 1999 Dec; 10(12):1441-9.
Score: 0.002
-
A new design for randomized trials. N Engl J Med. 1979 Oct 04; 301(14):786.
Score: 0.002
-
Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors. Clin Cancer Res. 1999 Jul; 5(7):1723-30.
Score: 0.002
-
Breast cancer in the eastern province of Saudi Arabia. Med Oncol. 1998 Dec; 15(4):241-7.
Score: 0.002
-
Transfusion management of an IgA deficient patient with anti-IgA and incidental correction of IgA deficiency after allogeneic bone marrow transplantation. Am J Hematol. 1998 Apr; 57(4):326-30.
Score: 0.001
-
Disposition of folic acid and its metabolites: a comparison with leucovorin. Clin Pharmacol Ther. 1994 May; 55(5):501-8.
Score: 0.001
-
CD34+ and CD33+ stem cells: predictors of hematologic recovery? Prog Clin Biol Res. 1992; 377:505-12.
Score: 0.001
-
A phase II trial of high-dose cytarabine and cisplatin in previously untreated non-small cell carcinoma of the lung. A Piedmont Oncology Association Study. Cancer. 1990 Apr 15; 65(8):1700-3.
Score: 0.001
-
Multimodality treatment of advanced head and neck carcinoma. J S C Med Assoc. 1989 Sep; 85(9):409-11.
Score: 0.001
-
The occurrence of a peripheral T-cell lymphoma in a chronically immunosuppressed renal transplant patient. Am J Surg Pathol. 1988 Jan; 12(1):64-70.
Score: 0.001
-
Nutritional support of bone marrow transplant recipients: a prospective, randomized clinical trial comparing total parenteral nutrition to an enteral feeding program. Cancer Res. 1987 Jun 15; 47(12):3309-16.
Score: 0.001
-
Platelet aggregation in patients with Laennec's cirrhosis of the liver. N Engl J Med. 1967 Jun 15; 276(24):1344-8.
Score: 0.001
-
Dye-mediated photolysis of normal and neoplastic hematopoietic cells. Leuk Res. 1987; 11(1):43-9.
Score: 0.001
-
Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med. 1986 Jul 17; 315(3):141-7.
Score: 0.001
-
Autologous bone marrow transplantation in acute leukemia: a phase I study of in vitro treatment of marrow with 4-hydroperoxycyclophosphamide to purge tumor cells. Blood. 1985 Jun; 65(6):1504-10.
Score: 0.001
-
Energy requirements of parenterally fed bone marrow transplant recipients. JPEN J Parenter Enteral Nutr. 1985 Mar-Apr; 9(2):139-43.
Score: 0.001
-
Nutritional assessment by isotope dilution analysis of body composition. Am J Clin Nutr. 1984 Oct; 40(4):847-54.
Score: 0.001
-
Antithoracic duct lymphocyte globulin therapy of severe aplastic anemia. Blood. 1983 Oct; 62(4):883-8.
Score: 0.001
-
Antigenic analysis of hematopoiesis. I. Expression of the My-1 granulocyte surface antigen on human marrow cells and leukemic cell lines. Blood. 1983 Jun; 61(6):1222-31.
Score: 0.001
-
Autologous bone marrow transplantation in acute leukemia and non-Hodgkin's lymphoma: a phase I study of 4-hydroperoxycyclophosphamide (4HC) incubation of marrow prior to cryopreservation. Haematol Blood Transfus. 1983; 28:90-1.
Score: 0.001
-
Parenteral trimethoprim-sulfamethoxazole and carbenicillin as empiric therapy for neutropenic patients with cancer. Rev Infect Dis. 1982 Mar-Apr; 4(2):586-92.
Score: 0.000